...
首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >The 5-Hydroxytryptamine_(2A)Receptor Is Involved in(+)-Norfenfluramine-lnduced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-Salt Hypertension
【24h】

The 5-Hydroxytryptamine_(2A)Receptor Is Involved in(+)-Norfenfluramine-lnduced Arterial Contraction and Blood Pressure Increase in Deoxycorticosterone Acetate-Salt Hypertension

机译:5-羟色胺_(2A)受体参与(+)-去甲氟拉明诱导的动脉收缩和醋酸脱氧皮质酮盐酸盐高血压的血压升高。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The highly effective anorexigen(+)-fenfluramine was widely used to control body weight until the association with primary pulmonary hypertension and valvular heart disease.(+)-Norfenfluramine is the major hepatic metabolite of(+)-fenfluramine and is primarily responsible for the anorexic effect as well as side effects.We reported that(+)-norfenfluramine causes vasoconstriction and a blood pressure increase in rats with normal blood pressure via the 5-hydroxytryptamine(5-HT)2A receptor.With the knowledge that(+)-norfenfluramine also has affinity for 5-HT_(2B)receptors and that arterial 5-HT_(2B)receptor expression is up-regulated in deoxycorticosterone acetate(DOCA)-salt hypertension,we tested the hypothesis that(+)-norfenfluramine-induced vasoconstriction and pressor effects are potentiated in DOCA-salt hypertensive rats in a 5-HT2 receptor-dependent manner.Contractions of arteries were measured using an isolated tissue bath system or myograph.Mean arterial blood pressure was measured in chronically instrumented conscious rats.Effects of(+)-norfenfluramine in stim-ulating arterial contraction(leftward shift versus SHAM,aorta,5.13-fold;renal artery,1.95-fold;mesenteric resistance artery,1.77-fold)and raising blood pressure were significantly enhanced in hypertension.In arteries from both normotensive and hypertensive rats,(+)-norfenfluramine-induced contraction in aorta was inhibited by 5-HT_(2A)receptor antagonists,ketanserin and LY53857(4-isopropyl-7-methyl-9-(2-hydroxy-1-meth ylpropoxycarbonyl)4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline),but not by the 5-HT_(2B)receptor antagonist,LY272015 [6-chloro-5-methyl-N-(5-quinolinyl)-2,3-dihydro-1H-indole-1-carboxamide].Ketanserin(3 mg/kg)reduced(+)-nor-fenfluramine-induced pressor response in both SHAM and DOCA rats.Our results demonstrate that(+)-norfenfluramine-induced arterial contraction and blood pressure increases are potentiated in DOCA-salt hypertensive rats.However,it is the 5-HT_(2A)receptor and not the 5-HT_(2B)receptor that participates in these effects.
机译:高效厌食素(+)-芬氟拉明被广泛用于控制体重,直到与原发性肺动脉高压和心脏瓣膜病相关。(+)-去甲氟拉明是(+)-芬氟拉明的主要肝脏代谢产物,主要负责我们报道了(+)-去甲氟拉明通过5-羟色胺(5-HT)2A受体引起正常血压的大鼠血管收缩和血压升高。诺芬氟拉明对5-HT_(2B)受体也具有亲和力,并且动脉5-HT_(2B)受体表达在醋酸脱氧皮质酮(DOCA)-盐高血压中上调,我们测试了(+)-诺芬氟拉明诱导的血管收缩的假说以5-HT2受体依赖性方式增强DOCA-盐高血压大鼠的血压和升压效果。使用独立的组织浴系统或肌电描记器测量动脉收缩力;测量平均动脉血压(+)-去甲氟拉明对刺激动脉收缩的作用(左移vs SHAM,主动脉,5.13倍;肾动脉,1.95倍;肠系膜阻力动脉,1.77倍)和血压升高在正常血压和高血压大鼠的动脉中,5-HT_(2A)受体拮抗剂,酮色林和LY53857(4-异丙基-7-甲基-9)抑制(+)-诺氟氟拉明诱导的主动脉收缩。 -(2-羟基-1-甲基丙基丙氧基羰基)4,6,6a,7,8,9,10,10a-八氢吲哚[4,3-fg]喹啉),但不是由5-HT_(2B)受体拮抗剂,LY272015 [6-氯-5-甲基-N-(5-喹啉基)-2,3-二氢-1H-吲哚-1-羧酰胺] .Ketanserin(3 mg / kg)还原(+)-去氟氟拉明-我们的结果表明,(+)-去甲氟拉明引起的动脉收缩和血压升高在DOCA-盐高血压大鼠中得到了增强,但是它是5-HT_(2A)受体而不是的参与这些作用的5-HT_(2B)受体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号